Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based ChemotherapyBusiness Wire • 09/15/23
Merck & Co., Inc. (MRK) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/11/23
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)Business Wire • 09/11/23
European Commission Expands Merck's ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and OlderBusiness Wire • 09/07/23
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in PediatricsBusiness Wire • 09/05/23
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceBusiness Wire • 09/05/23
Medicare drug price negotiations may have a muted impact on drugmakers in the near termCNBC • 08/30/23
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price CutsInvestors Business Daily • 08/29/23
Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiationsMarket Watch • 08/29/23
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)Business Wire • 08/29/23